<DOC>
	<DOC>NCT01566942</DOC>
	<brief_summary>the aim of this study is to observe the effect of irinotecan-based regimen in patients with advanced colorectal cancer.</brief_summary>
	<brief_title>FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>histologically confirmed adenocarcinoma in colorectal cancer clinical stage Ⅲ or Ⅳa(with potential radical resective metastatic lesions),≥ 12 lymph nodes examined no cancer cells were found in ascites Eastern Cooperative Oncology Group(ECOG) performance status of 02 male or female, between 18 and 75 years old adequate hematologic, hepatic and renal functions without severe heart disease in the last 6 months before enrolled. If with hypertension or coronary artery disease, it can be controlled not enrolled into others clinical trial during this study all patients should sign the informed consent can not be tolerated operation receiving others therapy(including Traditional Chinese herbs)for this disease, can not obey the investigator during the study can not be tolerated the adverse effect of drugs in these regimens major surgery within 4 weeks prior to study treatment start, or lack of complete recovery from major surgery metastatic disease more than one organ pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>FOLFIRI</keyword>
	<keyword>FOLFOX</keyword>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>advanced colorectal cancer</keyword>
</DOC>